News and Announcements
Latest coverage from Edison Research on Kazia’s recent initial efficacy data from its phase II trial of GDC-0084 in glioblastoma
- Published November 27, 2019 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
We’re pleased to provide the latest coverage from Edison Research on Kazia’s recent initial efficacy data from its phase II trial of GDC-0084 in glioblastoma.
The report states that the data is “very encouraging” and that it is “sufficient to give Kazia confidence that it can run a large, and potentially pivotal, study starting by mid-CY20.”
Edison also states that it assumes that this single pivotal trial might be adequate for FDA approval of GDC-0084 in 2024 “as patients resistant to the current standard therapy, temozolomide, have no other options available.”
Edison has a valuation on Kazia of A$137 million.
You can read the full research report, which includes a video interview with CEO, Dr James Garner, on GDC-0084 here
About KaziaTherapeutics Limited
Kazia Therapeutics Limited (ASX: KZA, NASDAQ: KZIA) is an innovative oncology-focused biotechnology company, based in Sydney, Australia. Our pipeline includes two clinical-stage drug development candidates, and we are working to develop therapies across a range of oncology indications.
Company Updates
Forget Startups: Why Magnetic Alliance is Betting on “Boring” Mid-Market Turnarounds
While Australia’s venture capital scene spent years chasing unprofitable tech startups and speculative high-growth plays, Mark Lim was quietly taking a radically different path. The Managing Partner of Magnetic Alliance Capital sees the nation’s richest investment opportunities hiding in plain sight: inside thousands of unglamorous, profitable, but operationally sluggish mid-market businesses. Speaking on Wholesale Investor’s […]
The asset class where the market has no vote
Litigation funding returns are decided in a courtroom, not a cycle. Knightsbridge’s Head of Capital is careful to call that a different risk rather than a lower one, and his answer to it is spread, not concentration. Most alternative assets still answer to something. Property answers to rates. Private credit answers to defaults. Even the […]
The listing fee vendors pay whether the house sells or not
Australia’s property portals collect more than $2 billion a year while national listings sit flat. An Australian-built AI platform is targeting the economics, not just the interface. An Australian vendor listing a home pays a vendor-paid advertising fee on top of agency commission. Rama Dwarapudi, Founder and Chief Executive Officer of RealSearch, puts a typical […]
Backed By Leading Investment Groups and Family Offices
